Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6017885 | 0.98 | CYP1A1 (0.58) | DCPSCYP1A2CYP1A1CYP1B1POLB | |
| SCHEMBL12261793 | 0.82 | DCPS (0.59) | DCPSCYP1A2CYP1A1CYP1B1POLB | |
| SCHEMBL28036770 | 0.81 | DCPS (0.49) | DCPSCYP1A2CYP1A1CYP1B1POLB | |
| SCHEMBL14964747 | 0.80 | KMT2A (0.55) | DCPSCYP1A2CYP1A1CYP1B1POLB | |
| SCHEMBL3023761 | 0.80 | TLR7 (0.50) | DCPSCYP1A2CYP1A1CYP1B1APP | |
| Hydrochloric Acid SCHEMBL3231113 | 0.79 | TLR7 (0.49) | DCPSCYP1A2CYP1A1CYP1B1APP | |
| SCHEMBL317214 | 0.78 | MAPT (0.56) | CYP1A2POLBMEN1KMT2ATSHR | |
| SCHEMBL29487316 | 0.78 | MAPT (0.56) | CYP1A2POLBMEN1KMT2ATSHR | |
| SCHEMBL26313710 | 0.78 | GPR3 (0.55) | CYP1A2POLBMEN1KMT2ATSHR | |
| SCHEMBL19100457 | 0.78 | PRNP (0.42) | POLBMEN1KMT2ATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521747-A4 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2006-10-11 | — | — | EP | claimed |
| EP-1521747-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-04-13 | — | — | EP | claimed |
| WO-2004006846-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | disclosed |
| US-20250262213-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2024016783-A1 | 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | 威尚（上海）生物医药有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| US-20230092892-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-03-23 | — | — | US | disclosed |
| EP-3778589-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| EP-1521747-A4 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1521747-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004006846-A2 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-4543356-A | Quinazoline derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-09-24 | — | — | US | disclosed |
| EP-0030156-B1 | QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-21 | — | — | EP | disclosed |
| US-4429126-A | ANTIASTHMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-01-31 | — | — | US | disclosed |
| US-4377580-A | ANTIALLERGENIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-03-22 | — | — | US | disclosed |
| EP-0030156-A1 | Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | DCPS 2974/4885CYP1A2 4004/4885CYP1A1 4011/4885 |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | FYN, KDR, FLT1 | DCPS 658/4885CYP1A2 2405/4885CYP1A1 3584/4885 |
| US-20250262213-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | DCPS 4210/4885CYP1A2 4081/4885CYP1A1 2806/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | DCPS 1362/4885CYP1A2 3697/4885CYP1A1 3756/4885 |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | FYN, KDR, FLT1 | DCPS 658/4885CYP1A2 2405/4885CYP1A1 3584/4885 |
| US-20230092892-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | DCPS 1005/4885CYP1A2 1183/4885CYP1A1 1181/4885 |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX7 | DCPS 1859/4885CYP1A2 877/4885CYP1A1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.